1625-72-5 Usage
Uses
Used in Organic Synthesis:
S-Cbz-L-cysteine is used as a building block for the synthesis of complex organic molecules. Its protected amine group allows for selective reactions and deprotection, facilitating the creation of a wide range of compounds.
Used in Peptide Chemistry:
In peptide chemistry, S-Cbz-L-cysteine serves as a crucial component for the assembly of peptides. The carbobenzyloxy protection ensures that the amine group can be selectively deprotected, enabling the formation of peptide bonds without unwanted side reactions.
Used in Pharmaceutical Industry:
S-Cbz-L-cysteine is used as an intermediate in the synthesis of pharmaceutical compounds. Its ability to be selectively deprotected and incorporated into complex molecules makes it a valuable tool in the development of new drugs.
Used in Chemical Research:
S-Cbz-L-cysteine is utilized in chemical research to study the properties and reactions of protected amino acids. Its unique reactivity and solubility characteristics make it an important subject of investigation in the field of chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 1625-72-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,6,2 and 5 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1625-72:
(6*1)+(5*6)+(4*2)+(3*5)+(2*7)+(1*2)=75
75 % 10 = 5
So 1625-72-5 is a valid CAS Registry Number.
InChI:InChI=1/C11H13NO4S/c12-9(10(13)14)7-17-11(15)16-6-8-4-2-1-3-5-8/h1-5,9H,6-7,12H2,(H,13,14)
1625-72-5Relevant articles and documents
S-NITROSOTHIOL COMPOUNDS AND RELATED DERIVATIVES
-
Page/Page column 52, (2008/12/06)
The present invention is directed to a method of treating a lack of normal breathing control including the treatment of apnea and hypoventilation associated with sleep, obesity, certain medicines and other medical conditions. In an aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a single compound which treats lack of normal breathing. In another aspect, the invention is directed to treating disordered control of breathing by administering an composition comprising a combination of two or more compounds, at least one of which treats lack of normal breathing. In an aspect, a compound is an S-nitrosylating agent.